A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer

BACKGROUND: We evaluated the efficacy of intraperitoneal (IP) carboplatin in combination with dose-dense paclitaxel (ddTCip) for suboptimal residual ovarian cancer. METHODS: This was a phase 2 study to evaluate ddTCip. Patients with stage II–IV ovarian carcinoma, who underwent primary cytoreductive...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasegawa, Kosei, Shimada, Muneaki, Takeuchi, Satoshi, Fujiwara, Hiroyuki, Imai, Yuichi, Iwasa, Norihiro, Wada, Satoru, Eguchi, Hidetaka, Oishi, Tetsuro, Sugiyama, Toru, Suzuki, Mitsuaki, Nishiyama, Masahiko, Fujiwara, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078205/
https://www.ncbi.nlm.nih.gov/pubmed/32001833
http://dx.doi.org/10.1038/s41416-020-0734-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078205/
https://www.ncbi.nlm.nih.gov/pubmed/32001833
http://dx.doi.org/10.1038/s41416-020-0734-9

Ejemplares similares